



Data Section

- Financial Data..... 99
- ESG (Environmental, Social, and Governance) Data..... 106
- Major Products..... 108
- Corporate Profile / Main Group Companies..... 110
- Shareholders' Information..... 112

Financial Data

Consolidated Statement of Profit or Loss

	(Millions of yen)	
	FY2015 (For the year ended March 31, 2016)	FY2016 (For the year ended March 31, 2017)
Revenue	986,446	955,124
Cost of sales	318,622	349,373
Gross profit	667,823	605,751
Selling, general and administrative expenses	328,755	302,475
Research and development expenses	208,656	214,347
Operating profit	130,412	88,929
Financial income	5,292	6,406
Financial expenses	13,028	7,710
Share of profit (loss) of investments accounted for using the equity method	(287)	162
Profit before tax	122,388	87,788
Income taxes	41,988	40,309
Profit for the year	80,399	47,479
Profit attributable to:		
Owners of the Company	82,282	53,466
Non-controlling interests	(1,883)	(5,987)
Profit for the year	80,399	47,479
Earnings per share		
Basic earnings per share (yen)	119.37	79.63
Diluted earnings per share (yen)	119.11	79.44

Consolidated Statement of Comprehensive Income

	(Millions of yen)	
	FY2015 (For the year ended March 31, 2016)	FY2016 (For the year ended March 31, 2017)
Profit for the year	80,399	47,479
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income	(18,942)	(9,366)
Remeasurements of defined benefit plans	(5,397)	1,840
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	(31,088)	(7,626)
Share of other comprehensive income of investments accounted for using the equity method	(11)	6
Other comprehensive income (loss) for the year	(55,439)	(15,146)
Total comprehensive income for the year	24,959	32,332
Total comprehensive income attributable to:		
Owners of the Company	26,961	38,309
Non-controlling interests	(2,001)	(5,976)
Total comprehensive income for the year	24,959	32,332

Consolidated Statement of Financial Position

ASSETS	(Millions of yen)	
	FY2015 (As of March 31, 2016)	FY2016 (As of March 31, 2017)
Current assets		
Cash and cash equivalents	222,159	246,050
Trade and other receivables	248,762	231,867
Other financial assets	493,768	552,896
Inventories	144,273	153,138
Other current assets	15,233	10,461
Subtotal	1,124,196	1,194,414
Assets held for sale	1,071	3,374
Total current assets	1,125,268	1,197,788
Non-current assets		
Property, plant and equipment	250,168	217,772
Goodwill	78,691	78,446
Intangible assets	210,395	217,044
Investments accounted for using the equity method	1,207	1,424
Other financial assets	168,189	140,856
Deferred tax assets	55,726	53,502
Other non-current assets	10,875	8,143
Total non-current assets	775,254	717,190
Total assets	1,900,522	1,914,979

LIABILITIES AND EQUITY	(Millions of yen)	
	FY2015 (As of March 31, 2016)	FY2016 (As of March 31, 2017)
Current liabilities		
Trade and other payables	241,831	219,759
Bonds and borrowings	20,000	—
Other financial liabilities	819	535
Income taxes payable	53,936	57,955
Provisions	28,335	41,223
Other current liabilities	34,770	6,285
Subtotal	379,694	325,758
Liabilities directly associated with assets held for sale	—	1,058
Total current liabilities	379,694	326,817
Non-current liabilities		
Bonds and borrowings	181,000	280,543
Other financial liabilities	9,148	9,069
Post-employment benefit liabilities	14,028	11,381
Provisions	12,287	16,350
Deferred tax liabilities	33,679	32,294
Other non-current liabilities	37,161	67,093
Total non-current liabilities	287,306	416,733
Total liabilities	667,000	743,550
Equity		
Equity attributable to owners of the Company		
Share capital	50,000	50,000
Capital surplus	103,927	103,750
Treasury shares	(64,155)	(113,952)
Other components of equity	146,717	124,489
Retained earnings	994,916	1,011,610
Total equity attributable to owners of the Company	1,231,406	1,175,897
Non-controlling interests		
Non-controlling interests	2,115	(4,469)
Total equity	1,233,521	1,171,428
Total liabilities and equity	1,900,522	1,914,979

Consolidated Statement of Changes in Equity

(Millions of yen)							
	Equity attributable to owners of the Company			Other components of equity			
	Share capital	Capital surplus	Treasury shares	Subscription rights to shares	Exchange differences on translation of foreign operations	Cash flow hedges	Financial assets measured at fair value through other comprehensive income
Balance as of April 1, 2015	50,000	105,267	(14,198)	1,760	106,202	(4,347)	65,419
Profit for the year	—	—	—	—	—	—	—
Other comprehensive income	—	—	—	—	(31,001)	—	(18,942)
Total comprehensive income for the year	—	—	—	—	(31,001)	—	(18,942)
Purchase of treasury shares	—	(201)	(50,037)	—	—	—	—
Cancellation of treasury shares	—	—	80	(45)	—	—	—
Share-based payments	—	—	—	220	—	—	—
Dividends	—	—	—	—	—	—	—
Acquisition of non-controlling interests	—	(1,138)	—	—	—	—	—
Transfer from other components of equity to retained earnings	—	—	—	—	(6)	4,347	23,109
Others	—	—	—	—	—	—	—
Total transactions with owners of the Company	—	(1,339)	(49,957)	175	(6)	4,347	23,109
Balance as of March 31, 2016	50,000	103,927	(64,155)	1,935	75,195	—	69,586
Profit for the year	—	—	—	—	—	—	—
Other comprehensive income	—	—	—	—	(7,626)	—	(9,366)
Total comprehensive income for the year	—	—	—	—	(7,626)	—	(9,366)
Purchase of treasury shares	—	(69)	(50,026)	—	—	—	—
Cancellation of treasury shares	—	—	230	(133)	—	—	—
Share-based payments	—	—	—	264	—	—	—
Dividends	—	—	—	—	—	—	—
Acquisition of non-controlling interests	—	(107)	—	—	—	—	—
Transfer from other components of equity to retained earnings	—	—	—	—	—	—	(5,366)
Others	—	—	—	—	—	—	—
Total transactions with owners of the Company	—	(177)	(49,796)	131	—	—	(5,366)
Balance as of March 31, 2017	50,000	103,750	(113,952)	2,067	67,568	—	54,853

(Millions of yen)						
	Equity attributable to owners of the Company			Other components of equity		
	Remeasurements of defined benefit plans	Total other components of equity	Retained earnings	Total equity attributable to owners of the Company	Non-controlling interests	Total equity
Balance as of April 1, 2015	—	169,034	993,953	1,304,057	2,984	1,307,041
Profit for the year	—	—	82,282	82,282	(1,883)	80,399
Other comprehensive income	(5,378)	(55,321)	—	(55,321)	(118)	(55,439)
Total comprehensive income for the year	(5,378)	(55,321)	82,282	26,961	(2,001)	24,959
Purchase of treasury shares	—	—	—	(50,239)	—	(50,239)
Cancellation of treasury shares	—	(45)	(34)	0	—	0
Share-based payments	—	220	—	220	—	220
Dividends	—	—	(48,456)	(48,456)	—	(48,456)
Acquisition of non-controlling interests	—	—	—	(1,138)	1,138	—
Transfer from other components of equity to retained earnings	5,378	32,828	(32,828)	—	—	—
Others	—	—	—	—	(5)	(5)
Total transactions with owners of the Company	5,378	33,004	(81,320)	(99,613)	1,133	(98,479)
Balance as of March 31, 2016	—	146,717	994,916	1,231,406	2,115	1,233,521
Profit for the year	—	—	53,466	53,466	(5,987)	47,479
Other comprehensive income	1,835	(15,157)	—	(15,157)	10	(15,146)
Total comprehensive income for the year	1,835	(15,157)	53,466	38,309	(5,976)	32,332
Purchase of treasury shares	—	—	—	(50,095)	—	(50,095)
Cancellation of treasury shares	—	(133)	(95)	1	—	1
Share-based payments	—	264	—	264	—	264
Dividends	—	—	(43,879)	(43,879)	—	(43,879)
Acquisition of non-controlling interests	—	—	—	(107)	(600)	(708)
Transfer from other components of equity to retained earnings	(1,835)	(7,202)	7,202	—	—	—
Others	—	—	—	—	(7)	(7)
Total transactions with owners of the Company	(1,835)	(7,071)	(36,772)	(93,817)	(608)	(94,425)
Balance as of March 31, 2017	—	124,489	1,011,610	1,175,897	(4,469)	1,171,428

Consolidated Statement of Cash Flows


	(Millions of yen)	
	FY2015 (For the year ended March 31, 2016)	FY2016 (For the year ended March 31, 2017)
Cash flows from operating activities		
Profit before tax	122,388	87,788
Depreciation and amortization	44,306	47,373
Impairment loss	4,730	26,459
Financial income	(5,292)	(6,406)
Financial expenses	13,028	7,710
Share of (profit) loss of investments accounted for using the equity method	287	(162)
(Gain) loss on sale and disposal of non-current assets	(7,739)	449
(Increase) decrease in trade and other receivables	(15,121)	15,148
(Increase) decrease in inventories	972	(10,951)
Increase (decrease) in trade and other payables	33,083	(16,979)
Others, net	18,875	13,398
Subtotal	209,519	163,828
Interest and dividends received	3,603	4,289
Interest paid	(1,397)	(1,511)
Income taxes paid	(37,443)	(30,371)
Net cash flows from operating activities	174,281	136,234
Cash flows from investing activities		
Payments into time deposits	(674,891)	(492,441)
Proceeds from maturities in time deposits	419,899	404,416
Acquisition of securities	(303,023)	(180,376)
Proceeds from sale of securities	618,423	219,049
Settlement of forward foreign exchange contract for sale of securities	(7,024)	—
Acquisitions of property, plant and equipment	(27,136)	(24,766)
Proceeds from sale of property, plant and equipment	5,546	2,403
Acquisition of intangible assets	(42,261)	(28,196)
Acquisition of subsidiary	(11,771)	—
Proceeds from sale of subsidiary	7,004	—
Payments for loans receivable	(1,616)	(71)
Proceeds from collection of loans receivable	1,913	1,472
Others, net	8,971	1,719
Net cash flows from investing activities	(5,967)	(96,792)
Cash flows from financing activities		
Proceeds from bonds and borrowings	0	100,000
Repayments of bonds and borrowings	(22,976)	(20,000)
Purchase of treasury shares	(50,239)	(50,095)
Proceeds from sale of treasury shares	0	1
Dividends paid	(48,468)	(43,889)
Others, net	(1,247)	(1,038)
Net cash flows from financing activities	(122,930)	(15,022)
Net increase (decrease) in cash and cash equivalents	45,383	24,419
Cash and cash equivalents at the beginning of the year	189,372	222,159
Effect of exchange rate change on cash and cash equivalents	(12,596)	(527)
Cash and cash equivalents at the end of the year	222,159	246,050

Historical Data

	Japanese GAAP					
	FY2007	FY2008	FY2009	FY2010	FY2011	FY2012
(Billions of yen)						
Financial Results						
Net sales	880.1	842.1	952.1	967.3	938.6	997.8
Overseas sales	358.6	373.2	482.3	489.7	469.0	486.6
Ratio of overseas sales to net sales (%)	40.7	44.3	50.7	50.6	50.0	48.8
Operating income	156.8	88.8	95.5	122.1	98.2	100.5
Ratio of operating income to net sales (%)	17.8	10.6	10.0	12.6	10.5	10.1
Net income (loss)	97.6	(215.4)	41.8	70.1	10.3	66.6
Research and development expenses	163.4	184.5	196.8	194.3	185.0	183.0
Ratio of research and development expenses to net sales (%)	18.6	21.9	20.7	20.1	19.7	18.3
Depreciation and amortization	38.7	40.5	45.9	43.9	46.3	41.4
Capital expenditure	21.1	19.6	29.7	37.3	62.9	65.1
Financial Position						
Total assets	1,487.8	1,494.5	1,489.5	1,480.2	1,518.4	1,644.0
Net assets	1,244.5	888.6	889.5	887.7	832.7	915.7
Per Share Information						
Basic net income per share (yen)	135.35	(304.22)	59.45	99.62	14.75	94.64
Net assets per share (yen)	1,730.09	1,226.04	1,215.62	1,206.12	1,143.52	1,253.86
Annual dividends per share (yen)	70	80	60	60	60	60
Main Financial Indicators						
Return on equity (ROE) (%)	7.8	(20.5)	4.9	8.2	1.3	7.9
Equity ratio (%)	83.6	57.7	57.4	57.4	53.0	53.7
Dividend on equity (DOE) (%)	4.0	5.4	4.9	5.0	5.1	5.0
Free cash flows*	17.2	(335.4)	172.8	78.1	(32.5)	19.9
Average exchange rates						
(USD / JPY)	114.28	100.54	92.86	85.72	79.07	83.11
(EUR / JPY)	160.52	143.49	131.16	113.13	108.96	107.15
Number of Employees						
	15,349	28,895	29,825	30,488	31,929	32,229

* Cash flows from operating activities + Cash flows from investing activities

Revenue




Note: Figures for fiscal 2011 and prior are based on Japanese GAAP, while figures for fiscal 2012 onward are based on IFRS.

	IFRS				
	FY2012	FY2013	FY2014	FY2015	FY2016
(Billions of yen)					
Financial Results					
Revenue	994.7	1,118.2	919.4	986.4	955.1
Overseas revenue	483.2	584.5	392.4	430.7	375.2
Ratio of overseas revenue to revenue (%)	48.6	52.3	42.7	43.7	39.3
Operating profit	98.7	111.6	74.4	130.4	88.9
Ratio of operating profit to revenue (%)	9.9	10.0	8.1	13.2	9.3
Profit attributable to owners of the Company	64.0	60.9	322.1	82.3	53.5
Research and development expenses	184.4	191.2	190.7	208.7	214.3
Ratio of research and development expenses to revenue (%)	18.5	17.1	20.7	21.2	22.4
Depreciation and amortization	45.3	51.5	42.0	44.3	47.4
Capital expenditure	65.1	49.2	36.3	23.3	23.9
Financial Position					
Total assets	1,684.9	1,854.0	1,982.3	1,900.5	1,915.0
Total equity	938.5	1,007.5	1,307.0	1,223.5	1,171.4
Per Share Information					
Basic earnings per share (yen)	90.96	86.57	457.56	119.37	79.63
Equity per share attributable to owners of the Company (yen)	1,287.94	1,392.03	1,852.28	1,801.90	1,772.99
Annual dividends per share (yen)	60	60	60	70	70
Main Financial Indicators					
Return on equity attributable to owners of the Company (ROE) (%)	7.4	6.5	28.2	6.5	4.4
Ratio of equity attributable to owners of the Company to total assets (%)	53.8	52.9	65.8	64.8	61.4
Ratio of dividends to equity attributable to owners of the Company (%)	4.9	4.5	3.7	3.8	3.9
Free cash flows	20.4	(124.1)	121.5	168.3	39.4
Average exchange rates (USD / JPY)	83.11	100.24	109.94	120.14	108.42
(EUR / JPY)	107.15	134.38	138.78	132.57	118.84
Number of Employees					
	32,229	32,791	16,428	15,249	14,670

Note: Results for fiscal 2012 in compliance with IFRS are restated for comparison purposes.

Operating Profit/Ratio of Operating Profit to Revenue



Note: Figures for fiscal 2011 and prior are based on Japanese GAAP, while figures for fiscal 2012 onward are based on IFRS.

ESG (Environmental, Social, and Governance) Data

■ Environmental

Promoting Environmental Management

Aspect	Classification	Item	Scope	Unit	FY2014	FY2015	FY2016
CO ₂	CO ₂ emissions		In Japan	t-CO ₂	178,511	176,157	176,732
			Global	t-CO ₂	475,296	243,402	236,162
	CO ₂ emissions by Greenhouse Gas Protocol	Scope 1	In Japan	t-CO ₂	89,743	85,045	91,662
			Global	t-CO ₂	171,580	115,243	115,474
Water resources	Water used		In Japan	1,000 m ³	11,624	11,868	10,986
			Global	1,000 m ³	12,140	12,531	11,534
	Wastewater		In Japan	1,000 m ³	10,490	10,834	9,934
			Global	1,000 m ³	10,937	11,288	10,370
	Effective water usage volume*1		Global	1,000 m ³	—	1,243	1,164
Waste	Waste generated		In Japan	t	24,120	19,676	20,588
			Global	t	22,359	21,764	22,756
	Final disposal rate		In Japan	%	0.68	0.46	0.69
Amount of office paper consumed		In Japan	Million sheets	58.98	54.69	53.55	

■ Social

Promoting Compliance Management

Aspect	Classification	Item	Scope	Unit	FY2014	FY2015	FY2016
Compliance	Compliance training*2		In Japan	Persons	384	354	436
	Training on Daiichi Sankyo Group Individual Conduct Principles	Ratio of employees participating in e-learning and group training	In Japan	%	—	100	100
			Outside Japan	%	—	100	100
	Compliance violations discovered through DS-hotline and reporting venues for sexual and power harassment		Non-consolidated	Cases	6	7	0
	Compliance training based on Corporate Integrity Agreement*3 in the United States		In Japan	Persons	74	37	125
			Outside Japan	Persons	1,094	772	2,001
	GVP*4 training	Ratio of GVP-related employees undergoing training	Non-consolidated	%	100	100	100
			Ratio of all employees (excluding GVP-related employees) undergoing training	Non-consolidated	%	98.4	98.6
Development-related training (including GCP)	Aggregate number of e-learning programs and group training sessions	Non-consolidated	Times	24	31	93	

Mutual Growth of Employees and the Company

Aspect	Classification	Item	Scope	Unit	FY2014	FY2015	FY2016
Employees	Number of employees by region*5	In Japan	In Japan	Persons	8,549	8,589	8,648
		Outside Japan	Outside Japan	Persons	7,879	6,660	6,022
		Total	Consolidated	Persons	16,428	15,249	14,670
	Employee data*5	Number of male employees	In Japan	Persons	6,788	6,631	6,643
			Outside Japan	Persons	—	3,290	3,088
		Number of female employees	In Japan	Persons	1,973	1,958	2,005
			Outside Japan	Persons	—	3,370	2,934
		Average years of service	In Japan	Years	18.0	17.6	18.7
		Percentage of female employees	In Japan	%	22.1	22.8	23.2
	Global		%	—	34.9	33.7	
	Percentage of women in managerial positions	In Japan	%	4.5	5.0	5.4	
		Global	%	—	20.5	22.6	
Challenged worker*5	Employment rate of people with physical or mental disabilities	In Japan	%	2.34	2.45	2.44	
Human resource development	Number of company-wide award winners*6	In Japan	Persons	46	49	47	
		Employee turnover rate*7	Global	%	—	—	5.3

*1 Water intake-Wastewater

*2 Total of training for new hires, newly appointed managerial employees, newly appointed executive candidates, and mid-career hires

*3 Corporate Integrity Agreement: An agreement regarding legal compliance

*4 Good Vigilance Practice: Standard for post-marketing safety control of pharmaceuticals

*5 Figures as of the settlement date of each Group company; figures for the number of employees (in Japan) and average years of service for fiscal 2014 are as of April 1 of the following fiscal year;

figures for the employment rate of people with physical or mental disabilities for fiscal 2014 are as of June 1

*6 Total number of employees who received prize from the culture-building and achievement awards

*7 Rate of employees retiring for personal reasons

Enhancement of Communication with Stakeholders

Aspect	Classification	Item	Scope	Unit	FY2014	FY2015	FY2016
Patients and medical professionals	Evaluation of corporate stance and MR activities	MRs rated (all responding physicians)*8	In Japan	Rank	First	First	First
		MRs rated (hospital doctors)*8	In Japan	Rank	First	First	First
		MRs rated (private-practice physicians)*8	In Japan	Rank	Second	First	First
		Number of inquiries received (pharmaceutical products)	In Japan	Cases	120,000	118,000	116,000
Shareholders	Dividends per share	Interim	Non-consolidated	Yen	30	40	35
		Year-end	Non-consolidated	Yen	30	30	35
		Total	Non-consolidated	Yen	60	70	70

Improving Access to Healthcare

Aspect	Classification	Item	Scope	Unit	FY2014	FY2015	FY2016
Social	Number of mobile healthcare field clinics	Number of activities	In India	Times	499	503	496
			In Cameroon	Times	1,773	1,758	0
			In Tanzania	Times	306	408	93
	Number of development projects conducted through the GHIT Fund*9				3	3	3

Social Contribution Activities

Aspect	Classification	Item	Scope	Unit	FY2014	FY2015	FY2016
Social	Amount of contributions		In Japan	¥ Million	2,549	2,176	2,003
	Number of visitors to our factories		In Japan	Persons	1,700	1,200	1,200
	Number of visitors to Kusuri Museum*10		Non-consolidated	Persons	14,695	13,674	14,793
Employees	Acquisition of volunteer leave		In Japan	Persons	20	15	9

■ Governance

Aspect	Classification	Item	Scope	Unit	FY2014	FY2015	FY2016
Governance	Structure of Board of Directors	Number of directors	Non-consolidated	Persons	10	10	10
		Number of outside directors	Non-consolidated	Persons	4	4	4
		Number of female directors	Non-consolidated	Persons	0	0	0
	Structure of Audit & Supervisory Board	Number of Audit & Supervisory Board members	Non-consolidated	Persons	4	4	4
		Number of Outside Audit & Supervisory Board members	Non-consolidated	Persons	2	2	2
		Number of Outside Audit & Supervisory Board members (female)	Non-consolidated	Persons	1	1	1
	Remuneration of Directors	Total	Non-consolidated	¥ Million	555	612	578
	Remuneration of Audit & Supervisory Board members	Total	Non-consolidated	¥ Million	105	105	105

*8 Conducted by ANTERIO Inc. (FY2014-FY2016)

*9 Global Health Innovative Technology Fund

*10 A venue which offers an entertaining, "experienced-based" learning opportunity to visitors, introducing medicine in an accessible, easy-to-understand way

Referenced Guidelines

- UN Global Compact
- Japanese Ministry of the Environment, "Environmental Reporting Guidelines, 2012 Edition"
- ISO 26000
- IIRC (International Integrated Reporting Council), "International Integrated Reporting Framework"

Major Products

Innovative Drugs

Brand Name (Generic Name)	Efficacy	Launched	Remarks
Japan [Daiichi Sankyo Co., Ltd.]			
<i>Efient</i> (<i>prasugrel</i>)	Antiplatelet agent	2014	Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion.
<i>PRALIA</i> (<i>denosumab</i>)	Treatment for osteoporosis	2013	Human monoclonal antibody that binds to RANKL. A subcutaneous injection for use once every six months as a novel treatment for osteoporosis.
<i>TENELIA</i> (<i>teneligliptin</i>)	Type 2 diabetes mellitus treatment	2012	DPP-4 (dipeptidyl peptidase-4) inhibitor. Inhibits the activity of DPP-4, an enzyme that inactivates incretin, which is a glucose-dependent insulin-releasing hormone excreted from the gastrointestinal tract, and thereby increases incretin concentration in blood and facilitates insulin release.
<i>RANMARK</i> (<i>denosumab</i>)	Treatment for bone complications caused by bone metastases from tumors	2012	Human monoclonal antibody that binds to RANKL. A new and effective treatment option for treating bone disorders stemming from multiple myeloma and bone metastases from solid tumors.
<i>LIXIANA</i> (<i>edoxaban</i>)	Anticoagulant	2011	Orally administered Factor Xa inhibitor. It is an anticoagulant that specifically, reversibly, and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Approved for the prevention of venous thromboembolism (VTE) in patients with lower limb orthopedic surgery.
<i>LIXIANA</i> (<i>edoxaban</i>)	Anticoagulant	2014	Approved for additional indications for the prevention of ischemic stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and recurrence prevention of venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary thromboembolism).
<i>NEXIUM</i> (<i>esomeprazole</i>)	Ulcer treatment	2011	Proton pump inhibitor. Licensed from AstraZeneca. It suppresses gastric acid secretion.
<i>Memary</i> (<i>memantine</i>)	Alzheimer's disease treatment	2011	N-methyl-D-aspartate (NMDA) receptor antagonist. Memantine slows down progression of dementia symptoms in patients with moderate to severe Alzheimer's disease.
<i>Inavir</i> (<i>laninamivir</i>)	Anti-influenza treatment	2010	Neuraminidase inhibitor that inhibits influenza viral proliferation. Treatment is completed with a single inhaled dosage.
<i>Urief</i> (<i>silodosin</i>)	Treatment for dysuria	2006	Selective alpha 1A-adrenoceptor antagonist that selectively blocks alpha 1A-adrenoceptors in the lower part of the urinary tract. Compared with other alpha blockers, it causes fewer side effects, such as orthostatic hypotension.
<i>Olmetec</i> (<i>olmesartan</i>)	Antihypertensive agent	2004	Angiotensin II receptor blocker. <i>Olmesartan</i> blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the angiotensin II receptor.
<i>Rezaltas</i>	Antihypertensive agent	2010	A combination of two antihypertensive drugs: calcium ion antagonist, <i>azelnidipine</i> , and an angiotensin II receptor blocker, <i>olmesartan medoxomil</i> .
<i>Cravit</i> (<i>levofloxacin</i>)	Synthetic antibacterial agent	1993	New quinolone antibacterial agent offering strong antibacterial action and a broad antibacterial spectrum. Injectable preparation has been added as part of life-cycle management.
<i>Artist</i> (<i>carvedilol</i>)	Treatment for hypertension, angina pectoris and chronic heart failure	1993	Beta blocker that selectively blocks beta-adrenaline receptors of the sympathetic nerve.
<i>Mevalotin</i> (<i>pravastatin</i>)	Antihyperlipidemic agent	1989	HMG-CoA reductase inhibitor (statin) that lowers blood cholesterol levels by inhibiting cholesterol synthesis in the liver.
<i>Omnipaque</i> (<i>iohexol</i>)	Contrast medium	1987	Nonionic contrast medium used to improve visibility of diagnostic X-ray imaging is inadequate.
<i>Loxonin</i> (<i>loxoprofen</i>)	Anti-inflammatory analgesic	1986	Nonsteroidal anti-inflammatory analgesic. <i>Loxonin</i> tablets and granules have strong analgesic activity with lowered gastric side effects. <i>Loxoprofen</i> is a prodrug and is not metabolized in the stomach but activated after absorption through the small intestine. Other formulations such as tape are also available as a part of life-cycle management.



Olmetec (Japan)



NEXIUM (Japan)



PRALIA (Japan)



Efient (Japan)



LIXIANA (Japan)



Memary (Japan)



RANMARK (Japan)



TENELIA (Japan)

Innovative Drugs

Brand Name (Generic Name)	Efficacy	Launched	Remarks
US [Daiichi Sankyo Inc.]			
<i>MOVANTIK</i> (<i>naloxegol</i>)	Opioid-induced constipation treatment	2015	First once-daily oral product approved by the FDA for the treatment of opioid-induced constipation (OIC) for adults with chronic non-cancer pain.
<i>SAVAYSA</i> (<i>edoxaban</i>)	Anticoagulant	2015	Orally administered Factor Xa inhibitor. It is an anticoagulant that specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Approved for indications to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF) and for the treatment of venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE)).
<i>Efient</i> (<i>prasugrel</i>)	Antiplatelet agent	2009	Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion.
<i>Benicar</i>	Antihypertensive agent	2002	<i>Benicar</i> : <i>Olmesartan</i>
<i>Benicar HCT</i>	Antihypertensive agent	2003	<i>Benicar HCT</i> : Combination of <i>olmesartan medoxomil</i> and <i>hydrochlorothiazide</i> (diuretic)
<i>AZOR</i> (<i>olmesartan</i>)	Antihypertensive agent	2007	<i>AZOR</i> : Combination of <i>olmesartan medoxomil</i> and <i>amlodipine besylate</i> (calcium channel blocker)
<i>TRIBENZOR</i>	Antihypertensive agent	2010	<i>TRIBENZOR</i> : Triple combination of <i>olmesartan medoxomil</i> , <i>hydrochlorothiazide</i> , and <i>amlodipine besylate</i>
<i>Welchol</i> (<i>colesevelam</i>)	Hypercholesterolemia treatment / type 2 diabetes mellitus treatment	2000	Bile acid sequestrant. Marketed as a drug for treatment of hypercholesterolemia. Gained approval also for type 2 diabetes mellitus indication as part of life-cycle management.
US [Luitpold Pharmaceuticals, Inc.]			
<i>Injectafer</i> (<i>ferric carboxymaltose injection</i>)	Anemia treatment	2013	Effective for patients who have intolerance to oral iron or who have had unsatisfactory response to oral iron or who have non-dialysis-dependent chronic kidney disease.
<i>Venofer</i> (<i>iron sucrose injection</i>)	Anemia treatment	2000	Iron replacement product. Effective for treatment of iron deficiency anemia in dialysis patients.
Europe [Daiichi Sankyo Europe GmbH]			
<i>LIXIANA</i> (<i>edoxaban</i>)	Anticoagulant	2015	Orally administered Factor Xa inhibitor. It is an anticoagulant that specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Approved for indications for the prevention of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and prevention of recurrent venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE)).
<i>Efient</i> (<i>prasugrel</i>)	Antiplatelet agent	2009	Inhibits platelet aggregation and reduces the incidence of artery stenosis and occlusion.
<i>Olmetec</i>	Antihypertensive agent	2002	<i>Olmetec</i> : <i>Olmesartan</i>
<i>Olmetec Plus</i>	Antihypertensive agent	2005	<i>Olmetec Plus</i> : Combination of <i>olmesartan medoxomil</i> and <i>hydrochlorothiazide</i> (diuretic)
<i>Sevikar</i> (<i>olmesartan</i>)	Antihypertensive agent	2009	<i>Sevikar</i> : Combination of <i>olmesartan medoxomil</i> and <i>amlodipine besylate</i> (calcium channel blocker)
<i>Sevikar HCT</i>	Antihypertensive agent	2010	<i>Sevikar HCT</i> : Triple combination of <i>olmesartan medoxomil</i> , <i>hydrochlorothiazide</i> , and <i>amlodipine besylate</i>

Generic Drugs

Brand Name (Efficacy)
Japan [Daiichi Sankyo Espha Co., Ltd.]
<i>levofloxacin</i> (Synthetic antibacterial agent)
<i>donepezil</i> (Alzheimer's disease treatment)
<i>telmisartan</i> (Antihypertensive agent)
<i>metformin</i> (Type 2 diabetes mellitus treatment)
<i>atorvastatin</i> (Antihyperlipidemic agent)

OTC Related Drugs

Brand Name (Efficacy)
Japan [Daiichi Sankyo Healthcare Co., Ltd.]
<i>Lulu</i> (Combination cold remedy)
<i>Daiichi Sankyo Ichoyaku</i> (Multi-ingredient digestive remedy)
<i>Loxonin S</i> (Antipyretic analgesic)
<i>Patecs</i> (Antiphlogistic analgesic for external use)
<i>Transino</i> (Melasma treatment)

Vaccines

Brand Name (Efficacy)
Japan [Kitasato Daiichi Sankyo Vaccine Co., Ltd., Japan Vaccine Co., Ltd.]
<i>ActHIB</i> (Haemophilus influenzae type b vaccine)
<i>Rotarix</i> (Rotavirus vaccine)
<i>Influenza HA Vaccine</i> (Seasonal influenza vaccine)
<i>Live Attenuated Measles / Rubella Combined Vaccine</i> (Measles and rubella vaccine)



MOVANTIK (US)



LIXIANA (Europe)



Loxonin S (OTC Related Drugs)



MINON series (OTC Related Drugs)



Injectafer (US)



levofloxacin (Generic Drugs)



Transino (OTC Related Drugs)



ActHIB (Vaccines)

Corporate Profile / Main Group Companies

Corporate Profile (As of April 1, 2017)

Company name: DAIICHI SANKYO COMPANY, LIMITED

Established: September 28, 2005

Business: Research and development, manufacturing, import, sales, and marketing of pharmaceutical products

Paid-in capital: ¥50,000 million

Headquarters: 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan

Branches: Sapporo, Tohoku, Tokyo, Chiba, Saitama, Yokohama, Kanetsu, Tokai, Kyoto, Osaka, Kobe, Chugoku, Shikoku, Kyushu

Japan	
Daiichi Sankyo Espha Co., Ltd.	●
Daiichi Sankyo Healthcare Co., Ltd.	● ▲ ■
Daiichi Sankyo Propharma Co., Ltd.	▲
Daiichi Sankyo Chemical Pharma Co., Ltd.	▲
Daiichi Sankyo RD Novare Co., Ltd.	■
Daiichi Sankyo Business Associe Co., Ltd.	
Daiichi Sankyo Happiness Co., Ltd.	
Kitasato Daiichi Sankyo Vaccine Co., Ltd.	● ▲ ■

●	Sales
▲	Manufacturing
■	Research and development

U.S.A.	
Daiichi Sankyo, Inc.	● ■
Luitpold Pharmaceuticals, Inc.	● ▲ ■
Plexxikon Inc.	■

●	Sales
▲	Manufacturing
■	Research and development

Europe	
Daiichi Sankyo Europe GmbH	● ▲ ■
Daiichi Sankyo Deutschland GmbH	●
Daiichi Sankyo France SAS	●
Daiichi Sankyo Italia S.p.A.	●
Daiichi Sankyo España, S.A.	●
Daiichi Sankyo UK Ltd.	●
Daiichi Sankyo (Schweiz) AG	●
Daiichi Sankyo Portugal, Unipessoal Lda.	●
Daiichi Sankyo Austria GmbH	●
Daiichi Sankyo Belgium N.V.-S.A.	●
Daiichi Sankyo Nederland B.V.	●
Daiichi Sankyo Ilac Ticaret Ltd. Sti.	●
Daiichi Sankyo Ireland Ltd.	●
Daiichi Sankyo Altkirch Sarl	▲

●	Sales
▲	Manufacturing
■	Research and development

ASCA*	
Daiichi Sankyo (China) Holdings Co., Ltd.	● ▲ ■
Daiichi Sankyo Taiwan Ltd.	●
Daiichi Sankyo Korea Co., Ltd.	●
Daiichi Sankyo (Thailand) Ltd.	●
Daiichi Sankyo Hong Kong Ltd.	●
Daiichi Sankyo Brasil Farmaceutica LTDA.	● ▲

●	Sales
▲	Manufacturing
■	Research and development

* Asia, South & Central America

Shareholders' Information

Common Stock (As of March 31, 2017)

Number of shares authorized:	2,800,000,000
Number of shares issued:	709,011,343
Number of shareholders:	95,735

Share Registrar

Mitsubishi UFJ Trust and Banking Corporation

Mailing address and telephone number:

Mitsubishi UFJ Trust and Banking Corporation
Corporate Agency Division

Shin-TOKYO Post Office
post office box No.29, 137-8081, Japan

Tel: 0120-232-711 (toll free within Japan)

Major Shareholders (As of March 31, 2017)

Name	Number of Shares Held (Thousands of shares)	Ratio (%)
The Master Trust Bank of Japan, Ltd. (trust account)	55,320	8.34
Japan Trustee Services Bank, Ltd. (trust account)	45,258	6.82
Nippon Life Insurance Company	35,776	5.39
Trust & Custody Services Bank, Ltd. as trustee for Mizuho Bank, Ltd. Retirement Benefit Trust Account re-entrusted by Mizuho Trust and Banking Co., Ltd.	14,402	2.17
Sumitomo Mitsui Banking Corporation	11,413	1.72
Japan Trustee Services Bank, Ltd. (trust account 5)	11,322	1.71
Employee stock ownership of Daiichi Sankyo Group	10,890	1.64
STATE STREET BANK WEST CLIENT-TREATY 505234	10,745	1.62
Japan Trustee Services Bank, Ltd. (trust account 7)	8,673	1.31
Mizuho Bank, Ltd.	8,591	1.30

Notes: 1. The Company holds 45,783,623 treasury shares, which are excluded from the above list.
2. Treasury shares are not included in the computing of equity stake.

Distribution of Shareholders (As of March 31, 2017)

